FEATURED

ISRG Reports July 16

There is a category of company Wall Street occasionally misprices not because the business is broken but because the growth is so consistent that investors stop asking interesting questions. Intuitive Surgical is that company right now.

Q2 2026 earnings are confirmed for July 16, after the close. The stock is sitting roughly 15% off its post-Q1 high and about 30% off its 52-week high of $603.88, despite zero deterioration in the fundamental story. That gap is worth examining carefully.

What Q1 2026 Said

Intuitive delivered a strong Q1 2026, with revenue accelerating 23% year over year to $2.77 billion and non-GAAP EPS of $2.50.

• Q1 2026 EPS: $2.53 (GAAP) vs. $2.27 estimate; Revenue: $2.866B vs. $2.763B estimate
• Total procedures: +17% year over year; Da Vinci +16%, Ion +39%
• Da Vinci 5 placements: 232 systems, up from 147 a year ago
• Total da Vinci installed base: 11,395 units (+12% year over year); Ion installed base: 1,041 units (+22%)
• Full-year procedure growth guidance: Raised to 13.5% to 15.5%

Recurring revenue was up 23% and accounted for 86% of total revenue. That is the razor-and-blades model working exactly as intended.

Da Vinci 5 utilization is already running ahead of the older Xi platform, driving U.S. utilization growth of 4% with after-hours procedures up 31%. Hospitals are getting more throughput from the same capital investment. That is a stickiness argument that is very hard to argue against.

The Part People Skip: Ion

Ion procedures grew 39% in Q1. The platform, focused on lung biopsies, is doing something strategically important: it diversifies Intuitive away from pure reliance on surgical procedure volumes.

This is portfolio diversification at the procedure level. For context, bariatric volumes have been pressured for several quarters by GLP-1 adoption. Ion’s growth offsets that drift. The full-year guidance raise happened while those offsets were actively working, and that is not an accident.

The Competitive Question Nobody Has Fully Answered

The da Vinci 5 made up 85% of U.S. system placements in Q1 2026. That pace of adoption is locking hospital capital budgets in before competitors can establish a meaningful U.S. foothold.

Johnson and Johnson submitted Ottava to the FDA for De Novo classification in January 2026. As of now, the system is not commercially available in any market. The FDA review is pending. So while the competitive threat is real and worth tracking, an imminent U.S. launch is not the base case for 2026.

There is also antitrust aftermarket litigation running in the background over EndoWrist instrument servicing. The court ruled with plaintiffs that the da Vinci robot and EndoWrist instruments occupy separate product markets for antitrust purposes, and that Intuitive holds monopoly power in the aftermarket for repair and replacement. Not a thesis-killer, but a risk that resurfaces periodically.

The AI Layer Nobody Is Fully Valuing

Intuitive is investing in data and digital infrastructure to build out AI-enabled capabilities. The company’s approach: layer capabilities starting with high-quality procedural data from surgeries, robotic data streams, and electronic medical records, then use AI to provide insights, reduce outcome variation, and assist in surgical learning.

Here is what makes this interesting. Intuitive has approximately 11,395 da Vinci systems globally, each generating structured procedural data no competitor can replicate without decades of comparable installations. That data moat is arguably the most underappreciated part of the long-term case. Slight tangent, but worth sitting with: this is less a medical device company and more a data platform that happens to operate inside operating rooms.

Forward Scenarios

• Bull: Q2 procedure volumes hit the high end of guidance, dV5 placements accelerate, Ion enters new indications, and the AI product roadmap gets fresh analyst attention. Stock reclaims its post-Q1 high and pushes back toward the $480 to $500 range.
• Base: Steady execution in line with guidance, dV5 upgrade cycle continues at current pace, no major competitive developments. Stock consolidates in the $420 to $450 range through and after earnings.
• Bear: Management baked in roughly 100 basis points of gross margin pressure from tariffs into FY26 guidance. If that worsens, or China and Japan hospital spending stays subdued, or J&J Ottava receives FDA clearance faster than expected, multiple compression follows any guidance miss.

Q2 2026 will tell you whether the procedure volume guidance was conservative or fair. Given Q1’s 17% growth against a 13.5% to 15.5% full-year range, there is meaningful room for the business to outperform its own forecast again. July 16 is when the market decides whether this pullback was noise or something more. That answer is about 10 days away.